Abstract Number: 2532 • 2017 ACR/ARHP Annual Meeting
The Relationship between the Degree of Skin Involvement and Joint Activity in Patients with Psa: Experience from the Corrona Registry
Background/Purpose: Prior studies have shown an inconsistent relationship between skin and joint symptoms in patients with comorbid PsO and PsA1-3. The objective of the…Abstract Number: 1118 • 2017 ACR/ARHP Annual Meeting
Diabetes and Gout: Real-World Evidence Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization
Background/Purpose: Gout and type 2 diabetes mellitus (T2DM) are common in the United States (US), but little is known about potential associations of T2DM and…Abstract Number: 2533 • 2017 ACR/ARHP Annual Meeting
Current Psa Therapy Impacts the Relationship between the Degree of Skin Invlovment and Joint Activity
Background/Purpose: Simultaneous control of joint symptoms and degree of skin involvement has been linked to improvement in health-related quality of life in patients with coexistent…Abstract Number: 1233 • 2017 ACR/ARHP Annual Meeting
Establishing and Maintaining a Volunteer Charity Rheumatology Clinic: One Clinic’s Experience
Establishing and Maintaining a Volunteer Charity Rheumatology Clinic: One Clinic’s Experience Background/Purpose: In 2015, about 16% of adults under age 65 in Tennessee were uninsured.…Abstract Number: 1382 • 2017 ACR/ARHP Annual Meeting
Characteristics of Patients with Rheumatoid Arthritis and Atlanto-Axial Pannus
Background/Purpose: Formation of pannus, an inflammatory tissue mass, in the atlanto-axial joint of the cervical spine is an important sequela of rheumatoid arthritis (RA). Atlanto-axial…Abstract Number: 1443 • 2017 ACR/ARHP Annual Meeting
Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. After more…Abstract Number: 1460 • 2017 ACR/ARHP Annual Meeting
Predictive Factors Associated with Successful Down-Titration of Biologics for Rheumatoid Arthritis Patients in Clinical Practice
Background/Purpose: Randomized clinical trials have shown that if a patient is in sustained remission, biological disease-modifying anti rheumatic drugs (bDMARDs) therapy can be tapered in…Abstract Number: 1468 • 2017 ACR/ARHP Annual Meeting
Abatacept Retention Rates, Overall and By Participating Country, and Prognostic Factors of Retention in Patients with RA: 2-Year Results from a Real-World Observational Study
Background/Purpose: ACTION (NCT02109666) was the first prospective international non-interventional study designed to provide long-term real-world data on abatacept retention in patients (pts) with RA. The…Abstract Number: 95 • 2017 ACR/ARHP Annual Meeting
Globalisation of Paediatric Musculoskeletal Matters’ (PMM)
Background/Purpose: paediatric musculoskeletal matters’ (PMM–www.pmmonline.org) is a free, evidence-based and peer reviewed open e-resource for paediatric musculoskeletal (MSK) medicine targeting non-MSK specialists. Since launch (Nov-2014)…Abstract Number: 1511 • 2017 ACR/ARHP Annual Meeting
Real-Life Performance of the ASAS Health Index in Routine Care of Patients with Spondyloarthritis
Background/Purpose: The ASAS Health Index (ASAS HI) have been developed to measure health and impairment in functioning in patients with spondyloarthritis (SpA). Its measurement properties…Abstract Number: 186 • 2017 ACR/ARHP Annual Meeting
Paediatric Musculoskeletal (MSK) Triage in the Community – Rightpath – a Pilot Study
Background/Purpose: We are piloting a children and young people (CYP) community-based triage (called Rightpath) based on a validated adult MSK triage model developed by Pennine…Abstract Number: 1517 • 2017 ACR/ARHP Annual Meeting
Effectiveness and Retention Rate of Certolizumab Pegol in Spondyloarthritis. Real Life Data
Background/Purpose: Certolizumab pegol (CZP) is available for patients with spondyloarthritis (SpA), including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axialSpA). CZP has a different molecular…Abstract Number: 433 • 2017 ACR/ARHP Annual Meeting
Predictors of Earlier Biologic Initiation Among Patients with Rheumatoid Arthritis Starting Methotrexate
Background/Purpose: Biologic therapy for the treatment of RA has increased dramatically and has substantially increased costs of care. This study aimed to identify factors associated…Abstract Number: 1548 • 2017 ACR/ARHP Annual Meeting
Opioid Use in Patients with Ankylosing Spondylitis
Background/Purpose: The use or misuse of opioids has become a major public health issue in the USA. It is estimated that the economic burden of…Abstract Number: 538 • 2017 ACR/ARHP Annual Meeting
Severe Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. It is…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 8
- Next Page »